Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir

T-Reuters2021-07-17

Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

EHG
2021-07-19
EHG
Like
7a1f5064
2021-07-18
7a1f5064
Hello
CPKoh
2021-07-18
CPKoh
Great
Kukudosmin
2021-07-18
Kukudosmin
Ok
Ei_888
2021-07-18
Ei_888
Ok
Tomcatanty
2021-07-18
Tomcatanty
Wow
- Ei_888:
  👌
- sh99:
  harishan

发表看法

170

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2152894306?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-17 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2152894306","market":"us","top_or_hot":-1,"title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","media":"T-Reuters","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n2021-07-17 18:22 北京时间&nbsp;&nbsp;&nbsp;<strong>T-Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":null,"article_id":"2152894306","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","pubTimestamp":1626517346,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc."},"translate_title":"Gilead说3期数据支持Lenacapavir的持续长效疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APR":0.9,"CGEM":0.9,"GILD":0.9,"LABP":0.9,"LHDX":0.9,"SANA":0.9},"content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":173172925,"gmtCreate":1626650651267,"gmtModify":1633925344242,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586941861951066","authorIdStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173172925","repostId":2152894306,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173358549,"gmtCreate":1626620932581,"gmtModify":1633925450318,"author":{"id":"4089720653683940","authorId":"4089720653683940","name":"7a1f5064","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089720653683940","authorIdStr":"4089720653683940"},"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173358549","repostId":2152894306,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173336399,"gmtCreate":1626614396911,"gmtModify":1633925490389,"author":{"id":"3561517799283339","authorId":"3561517799283339","name":"CPKoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561517799283339","authorIdStr":"3561517799283339"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173336399","repostId":2152894306,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173339540,"gmtCreate":1626614006480,"gmtModify":1633925493968,"author":{"id":"4087297462574060","authorId":"4087297462574060","name":"Kukudosmin","avatar":"https://static.tigerbbs.com/fe82a55d4d107e643c3d79336bd97bb3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087297462574060","authorIdStr":"4087297462574060"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173339540","repostId":2152894306,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173004582,"gmtCreate":1626582475346,"gmtModify":1633925678597,"author":{"id":"3585533261543358","authorId":"3585533261543358","name":"Ei_888","avatar":"https://static.tigerbbs.com/117fa34406876f996514937472ec57e6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585533261543358","authorIdStr":"3585533261543358"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173004582","repostId":2152894306,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179748031,"gmtCreate":1626580777523,"gmtModify":1633925700336,"author":{"id":"4088424873177630","authorId":"4088424873177630","name":"Tomcatanty","avatar":"https://static.tigerbbs.com/815fae20f153a61faa55342edbb559b3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088424873177630","authorIdStr":"4088424873177630"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/179748031","repostId":2152894306,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5252811,"gmtCreate":1626582470075,"gmtModify":1635226823577,"authorId":3585533261543358,"author":{"id":3585533261543358,"idStr":"3585533261543358","authorId":3585533261543358,"name":"Ei_888","avatar":"https://static.tigerbbs.com/117fa34406876f996514937472ec57e6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179748031,"type":1,"supId":0,"prevId":0,"content":"👌","text":"👌","html":"👌"},{"id":5254174,"gmtCreate":1626602665222,"gmtModify":1635226703204,"authorId":3582013951378523,"author":{"id":3582013951378523,"idStr":"3582013951378523","authorId":3582013951378523,"name":"sh99","avatar":"https://static.tigerbbs.com/95985dfcd15851145b63b9903fdb5bfc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179748031,"type":1,"supId":0,"prevId":0,"content":"harishan","text":"harishan","html":"harishan"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":170,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2152894306"}